公开(公告)号：US20160122324A1

公开(公告)日：2016-05-05

申请号：US14994710

申请日：2016-01-13

Applicant: Novartis AG

Inventor： Shenlin Huang ,  Xianming Jin ,  Zuosheng Liu ,  Daniel Poon ,  John Tellew ,  Yongqin Wan ,  Xing Wang ,  Yongping Xie

IPC: C07D403/04

CPC classification number: C07D403/04 ,  A61K9/0053 ,  A61K31/4184 ,  A61K31/506 ,  A61K45/06 ,  C07D401/14 ,  C07D405/14 ,  A61K2300/00

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

公开(公告)号：US09314464B2

公开(公告)日：2016-04-19

申请号：US13931111

申请日：2013-06-28

Applicant: Novartis AG

Inventor： Shenlin Huang ,  Xianming Jin ,  Zuosheng Liu ,  Daniel Poon ,  John Tellew ,  Yongqin Wan ,  Xing Wang ,  Yongping Xie

IPC: A61K31/535 ,  A61K31/506 ,  C07D401/14 ,  C07D403/04 ,  A61K45/06 ,  C07D405/14

CPC classification number: C07D403/04 ,  A61K9/0053 ,  A61K31/4184 ,  A61K31/506 ,  A61K45/06 ,  C07D401/14 ,  C07D405/14 ,  A61K2300/00

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

公开(公告)号：US11234977B2

公开(公告)日：2022-02-01

申请号：US16956527

申请日：2018-12-19

Applicant: Novartis AG

Inventor： Jiping Fu ,  Wooseok Han ,  Xianming Jin ,  Keith Bruce Pfister ,  Joseph Michael Young

IPC: C07D471/14 ,  A61K31/4985 ,  A01N43/90 ,  A61P31/20 ,  A61K47/60 ,  A61K38/21 ,  A61K45/06

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US10093673B2

公开(公告)日：2018-10-09

申请号：US15782722

申请日：2017-10-12

Applicant: Novartis AG

Inventor： Jiping Fu ,  Xianming Jin ,  Patrick Lee ,  Peichao Lu ,  Joseph Michael Young

IPC: C07D491/147 ,  C07D471/14 ,  A61K31/4375 ,  C07D217/08 ,  C07D491/14

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20160120866A1

公开(公告)日：2016-05-05

申请号：US14994827

申请日：2016-01-13

Applicant: Novartis AG

Inventor： Shenlin Huang ,  Xianming Jin ,  Zuosheng Liu ,  Daniel Poon ,  John Tellew ,  Yongqin Wan ,  Xing Wang ,  Yongping Xie

IPC: A61K31/506 ,  A61K31/4184 ,  A61K9/00

CPC classification number: C07D403/04 ,  A61K9/0053 ,  A61K31/4184 ,  A61K31/506 ,  A61K45/06 ,  C07D401/14 ,  C07D405/14 ,  A61K2300/00

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.